AstraZeneca: FDA approves drug for metastatic breast cancer
(CercleFinance.com) - U.
S. health regulators have approved a drug made by AstraZeneca and Japan's Daiichi for some patients with breast cancer who failed to respond to other treatments, the companies said.
The Food and Drug Administration (FDA) has approved Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens.
This specifically engineered HER2-directed antibody-drug has shown "impressive" results, with the majority of women benefiting from treatment and the median duration of the response exceeding 14 months, AstraZeneca said.
AstraZeneca also said on Monday that that its budesonide/glycopyrronium/formoterol fumarate triple-combination therapy has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
S. health regulators have approved a drug made by AstraZeneca and Japan's Daiichi for some patients with breast cancer who failed to respond to other treatments, the companies said.
The Food and Drug Administration (FDA) has approved Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens.
This specifically engineered HER2-directed antibody-drug has shown "impressive" results, with the majority of women benefiting from treatment and the median duration of the response exceeding 14 months, AstraZeneca said.
AstraZeneca also said on Monday that that its budesonide/glycopyrronium/formoterol fumarate triple-combination therapy has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Copyright (c) 2019 CercleFinance.com. All rights reserved.